PrEP Truvada Oral denied as not FDA-approved for this use by Cigna?

Cigna's specific coverage criteria for prep truvada oral are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Cigna Denied PrEP (Truvada) as Not FDA-Approved

A "not FDA-approved" denial for oral Truvada used as HIV pre-exposure prophylaxis (PrEP) is almost certainly an administrative or coding error. The FDA granted a specific PrEP indication for this medication; it is not an off-label use. When this denial appears, it typically means the prior-authorization request was coded incorrectly (wrong diagnosis code, wrong indication flag, or a generic drug substitution that altered the product identifier), or that Cigna's system did not match the submitted drug to its approved indication.

## Why This Denial Is Appealable

An insurer cannot deny coverage on the basis of lack of FDA approval when FDA approval plainly exists for the submitted indication. This type of denial is factually incorrect and should be corrected at the earliest possible stage — either through a rapid appeal or by working with your prescriber's office to correct a coding error before the formal appeal. If correction is not possible administratively, the appeal record should include the FDA approval documentation directly.

## Federal Appeal Framework

• Administrative correction (first step): Before filing a formal appeal, ask your prescriber's office to verify that the diagnosis code and drug code submitted match the FDA-approved PrEP indication precisely. A resubmission with corrected codes often resolves this faster than a formal appeal.
• Internal appeal (ACA §2719 / ERISA §503): If resubmission does not resolve the denial, file a formal internal appeal with the FDA prescribing information attached. The denial letter states the appeal deadline — preserve it.
• External review: If the internal appeal fails, you may request independent IRO review at no cost, generally within four months of the final denial. Expedited review is available when health is at serious risk.

## Concrete Appeal Process and Timeline

1. Contact your prescriber's office to verify the codes submitted on the prior-authorization. 2. Pull the FDA-approved prescribing information for oral Truvada confirming the PrEP indication (available at FDA.gov). 3. Submit a corrected prior-authorization or a formal internal appeal with the FDA label attached. 4. If denied at internal level, escalate to external IRO review.

## Documentation to Gather

• FDA prescribing information: The current FDA-approved label explicitly identifying the PrEP indication — this is your primary rebuttal document.
• Correct diagnosis and drug codes: Confirmation from your prescriber's office that ICD-10 diagnosis codes and drug codes match the FDA-approved indication.
• HIV-negative status: Current lab results confirming you are HIV-negative, consistent with PrEP candidacy.
• Prescriber letter: A brief letter from your provider confirming the drug is being prescribed for its FDA-approved PrEP indication and that this is not an off-label use.

## Criteria-Mapping Structure

For every basis Cigna cites for the "not FDA-approved" determination, map it to a rebuttal:

| Cigna Denial Basis | Rebuttal Evidence | |---|---| | [Copy exact language from denial] | [FDA label page/section, corrected code, or prescriber attestation] |

Because this denial is factually incorrect when PrEP is the prescribed indication, a concise and well-documented rebuttal — anchored to the FDA label — is typically sufficient to overturn it.